A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies
more »
- University of Pennsylvania, Philadelphia, PA (United States)
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Duke University School of Medicine, Durham, NC (United States)
- University of Pennsylvania, Philadelphia, PA (United States); The Wistar Institute, Philadelphia, PA (United States)
- The Scripps Research Institute, La Jolla, CA (United States)
- Centre de Recherche du CHUM, Montreal, QC (Canada); Univ. of Montreal, QC (Canada)
- Bioqual, Inc., Rockville, MD (United States)
- National Institutes of Health (NIH), Bethesda, MD (United States)
- San Diego Biomedical Research Institute, CA (United States)
- The Scripps Research Institute, La Jolla, CA (United States); Ragon Institute of MGH, Harvard and MIT, Cambridge, MA (United States)
HIV-1 and its SIV precursors share a broadly neutralizing antibody (bNAb) epitope in variable loop 2 (V2) at the envelope glycoprotein (Env) trimer apex. Here, we tested the immunogenicity of germ line-targeting versions of a chimpanzee SIV (SIVcpz) Env in human V2-apex bNAb heavy-chain precursor-expressing knock-in mice and as chimeric simian-chimpanzee immunodeficiency viruses (SCIVs) in rhesus macaques (RMs). Trimer immunization of knock-in mice induced V2-directed NAbs, indicating activation of V2-apex bNAb precursor-expressing mouse B cells. SCIV infection of RMs elicited high-titer viremia, potent autologous tier 2 neutralizing antibodies, and rapid sequence escape in the canonical V2-apex epitope. Six of seven animals also developed low-titer heterologous plasma breadth that mapped to the V2-apex. Antibody cloning from two of these animals identified multiple expanded lineages with long heavy chain third complementarity determining regions that cross-neutralized as many as 7 of 19 primary HIV-1 strains, but with low potency. Negative stain electron microscopy (NSEM) of members of the two most cross-reactive lineages confirmed V2 targeting but identified an angle of approach distinct from prototypical V2-apex bNAbs, with antibody binding either requiring or inducing an occluded-open trimer. Probing with conformation-sensitive, nonneutralizing antibodies revealed that SCIV-expressed, but not wild-type SIVcpz Envs, as well as a subset of primary HIV-1 Envs, preferentially adopted a more open trimeric state. These results reveal the existence of a cryptic V2 epitope that is exposed in occluded-open SIVcpz and HIV-1 Env trimers and elicits cross-neutralizing responses of limited breadth and potency.
- Research Organization:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Organization:
- Canada Research Chair on Retroviral Entry; Canadian Institutes of Health Research (CIHR); National Institutes of Health (NIH); USDOE
- Grant/Contract Number:
- 89233218CNA000001
- OSTI ID:
- 2470552
- Journal Information:
- mBio (Online), Journal Name: mBio (Online) Journal Issue: 1 Vol. 14; ISSN 2150-7511
- Publisher:
- American Society for Microbiology (ASM)Copyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Immunization of cows with HIV envelope trimers generates broadly neutralizing antibodies to the V2-apex from the ultralong CDRH3 repertoire
Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer
Journal Article
·
Sun Sep 08 20:00:00 EDT 2024
· PLoS Pathogens
·
OSTI ID:2582882
Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer
Journal Article
·
Wed Nov 16 19:00:00 EST 2022
· PLoS Pathogens
·
OSTI ID:2423892